Clinical trials: Oligometastatic Prostate Carcinoma, open to volunteers
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who are at risk of having their disease spread to the lymph…
- Conditions
- Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06389786
- Testing
- Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Oligometastatic Prostate Cancer
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
This study is a multicenter, randomized controlled phase III clinical trial (PROLONG-3) designed to evaluate the survival benefit of comprehensive radiotherapy combined with primary tumor radiotherapy versus primary tumor…
- Trial name
- PROLONG-3 (NCT07015138)
- Testing
- TRT, NTRT
- Where
- 3 sites in China
- Volunteers
- 390 people
- Sponsor
- Peking University First Hospital
Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease
The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones.
- Conditions
- Prostate Cancer (Adenocarcinoma), OligoProgressive Metastatic Disease, Castration Resistant Metastatic Prostate Cancer, Radiotherapy
- Trial name
- OLYMPIAN (NCT07038304)
- Testing
- Metastasis directed radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 35 people
- Sponsor
- University Medical Center Groningen
Oligometastatic Prostate Cancer
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission…
- Trial name
- POPSTAR II (NCT05560659)
- Testing
- 177Lu-PSMA
- Where
- 3 sites in Australia, Israel
- Volunteers
- 92 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Oligometastatic Prostate Cancer
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive…
- Trial name
- SBRT-AMICO (NCT05915442)
- Testing
- Quemliclustat, Etrumadenant, Zimberelimab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Catherine Spina
Prostate Cancer, Oligo-metastatic Prostate Carcinoma
MR-guided Single-fraction SBRT for Nodal Oligorecurrent Prostate Cancer (PINPOINT)
This single-arm phase 2 trial investigates whether a single high-dose radiotherapy treatment can safely treat men whose prostate cancer has come back in a small number of lymph nodes in the pelvis or abdomen after curative…
- Conditions
- Prostate Cancer, Oligo-metastatic Prostate Carcinoma, Oligometastatic Cancer, Nodal Oligorecurrent Prostate Cancer
- Trial name
- PINPOINT (NCT07635108)
- Testing
- Single-fraction SBRT
- Where
- Denmark
- Volunteers
- 48 people
- Sponsor
- Odense University Hospital
Prostate Cancer Patients, Non-castrate Prostate Cancer
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells.
- Conditions
- Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
- Trial name
- NCT07090148
- Testing
- pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Locally Advanced and Metastatic Prostate Cancer
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer
Prostate cancer is the most common non-skin cancer diagnosed among men and the second leading cause of male cancer deaths in the United States. In 2013, it is estimated that 29,270 men have died from prostate cancer.
- Trial name
- NCT02971358
- Testing
- Radical prostatectomy
- Where
- Austria
- Volunteers
- 200 people
- Sponsor
- Medical University of Vienna
Oligometastatic Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate…
- Trial name
- PROMPT (NCT04610372)
- Testing
- Hypofractionated external beam radiotherapy, High dose rate brachytherapy, Permanent seed implant
- Where
- 4 sites in Canada
- Volunteers
- 168 people
- Sponsor
- British Columbia Cancer Agency
Prostatic Neoplasms, Biochemical Recurrence
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)
The goal of this clinical trial is to learn if adding metastasis-directed radiotherapy with or without pelvic salvage radiotherapy, to intermittent prostate cancer drugs (intensified hormone therapy) can delay the need to restart…
- Conditions
- Prostatic Neoplasms, Biochemical Recurrence, Oligometastatic Prostate Cancer
- Trial name
- ESCALATE-RT (NCT07782112)
- Testing
- Radiotherapy for MDT ± WPRT, Androgen Deprivation Therapy (ADT), Enzalutamide
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 140 people
- Sponsor
- Ente Ospedaliero Cantonale, Bellinzona
Prostate Cancer, Metastatic Prostate Cancer
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
This is an ambispective, multicenter, observational real-world registry of patients with synchronous de novo oligometastatic prostate cancer, defined as prostate cancer with up to 10 extraregional metastatic lesions diagnosed at…
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Oligometastatic Prostate Cancer, Synchronous Oligometastatic Prostate Cancer
- Trial name
- SynSABR-PC (NCT07686016)
- Testing
- Definitive Prostate-Directed Radiotherapy, Metastasis-Directed Stereotactic Body Radiotherapy, Pelvic Lymph Node Irradiation
- Where
- Poland
- Volunteers
- 700 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Prostate Cancer, Radiotherapy Side Effect
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer 2.
- Conditions
- Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
- Trial name
- SMART-P01/02 (NCT05183074)
- Testing
- MR-linac
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Prostate Cancer, Oligometastatic
Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE
The goal of this clinical trial is to learn whether radioguided surgery can help surgeons find and remove lymph nodes containing prostate cancer in men whose cancer has returned in a small number of lymph nodes after previous…
- Trial name
- SALVAGE (NCT07807293)
- Testing
- PSMA 99mTc-MIP-1404 radioguided salvage lymph node dissection, Salvage pelvic lymph node dissection
- Volunteers
- 62 people
- Sponsor
- University of British Columbia
Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
JUR-003 in Adult Patients With Metastatic Prostate Cancer
JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer.
- Conditions
- Metastatic Castration Resistant Prostate Cancer, Oligometastatic Prostate Cancer (OMPC), Metastatic Hormone Sensitive Prostate Cancer
- Trial name
- NCT07824349
- Testing
- JUR-003
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Juri Biosciences, Inc.
Prostate Cancer, Oligometastatic Disease
TERPS Trial for de Novo Oligometastic Prostate Cancer
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
- Trial name
- NCT05223803
- Testing
- Prostate radiation (XRT), Systemic Therapy, Stereotactic ablative radiation therapy (SABR)
- Where
- 10 sites in United States
- Volunteers
- 122 people
- Sponsor
- University of Maryland, Baltimore
Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.
- Trial name
- SEGNO (NCT06387056)
- Testing
- Rezvilutamide, Goserelin Microspheres for Injection, Docetaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Prostate Cancer
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Prospective single-center phase II study to evaluate the PSA, imaging and pathological response, as well as oncological outcomes of systemic radioligand therapy [177Lu]Lu-PSMAI\&T (PSMA-RLT) in patients planned for radical…
- Trial name
- NCT06259123
- Testing
- [177Lu]Lu-PSMA I&T
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Prostate Cancer
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Multicenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone.
- Trial name
- LUST (NCT05893381)
- Testing
- [177Lu]Lu-PSMA I&T, Stereotactic Radiotherapy
- Where
- 2 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
High Risk Prostate Cancer
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
This is a phase 2, open-label, randomized study of adjuvant treatment in subjects with high-risk prostate cancer who are candidates for RP with PLND based on M0 status at conventional imaging, but staged as oligometastatic with…
- Trial name
- STAPLE (NCT06758882)
- Testing
- Apalutamide, Androgen receptor (AR) inhibitor
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- Marco Oderda
Oligometastatic Prostate Cancer
Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
Prostate cancer represents the second most common malignancy in men worldwide. Oligometastatic prostate cancer (OMPC), defined as a transitional state between localized and widespread metastatic disease (≤10 metastatic lesions…
- Trial name
- OMPC-RPM (NCT07490210)
- Testing
- Metastasis-directed radiotherapy, Rezvilutamide + ADT, Radical prostatectomy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Fudan University